The Emerging Nanomedicine Landscape

The surge in Nanomedicine research activity over the past decade is now translating into considerable commercialisation efforts around the world. More than 150 start-ups and SMEs worldwide pursue focussed Nanomedicine R&D projects and about 38 Nanotechnology-enabled products with total sales valued at $ 6.8 billion are now on the market. With regards to commercialisation efforts, the USA leads the field with twice as much Nanomedicine patent applications and 25 % more products on the market compared to EU-25 countries. At present, the development in Nanomedicine is still much technology-driven. Scientific challenges lie ahead and much needed investment by pharmaceutical corporations to bring products to the market is lacking. Despite these stumbling blocks, Nanotechnology is anticipated to have an increasing impact on medical innovations in the future.

BOCK Anne-Katrin; 

2006-12-13

NATURE PUBLISHING GROUP

JRC34520